Gossamer Bio, Inc. announced the final tender results for its exchange offer to exchange 5.00% Convertible Senior Notes due 2027 for up to $72.0 million in aggregate principal amount of new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, and warrants. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic solutions for inflammatory and inflammatory-related diseases.
